How have MNOV shares performed in 2024?

MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV shares have decreased by 4.7% and is now trading at $1.43. View the best growth stocks for 2024 here .

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MNOV earnings forecast .

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , OPKO Health (OPK) , Iovance Biotherapeutics (IOVA) , Novavax (NVAX) , Rigel Pharmaceuticals (RIGL) , Trevena (TRVN) , Viking Therapeutics (VKTX) , Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY) .

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free MNOV Stock Alerts

$1.42

-0.01 (-0.70%)

(As of 09:30 AM ET)

Compare

Today's Range: $1.42
▼
$1.42
50-Day Range: $1.28
▼
$1.57
52-Week Range: $1.26
▼
$2.66

Volume: 206 shs
Average Volume: 55,216 shs
Market Capitalization: $69.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get MediciNova alerts:

MediciNova MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
0.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.23) to ($0.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.11 out of 5 stars

Medical Sector

904th out of 913 stocks

Pharmaceutical Preparations Industry

416th out of 421 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for MediciNova.

2.0

Short Interest

Percentage of Shares Shorted
0.72% of the float of MediciNova has been sold short.
Short Interest Ratio / Days to Cover
MediciNova has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in MediciNova has recently increased by 2.33%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
MediciNova does not currently pay a dividend.
Dividend Growth
MediciNova does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNOV.

3.1

News and Social Media Coverage

News Sentiment
MediciNova has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MediciNova this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for MNOV on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediciNova insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.90% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.90% of the stock of MediciNova is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MediciNova are expected to decrease in the coming year, from ($0.23) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MediciNova is -8.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MediciNova is -8.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MediciNova has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About MediciNova Stock (NASDAQ:MNOV)

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MNOV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MNOV Stock News Headlines

April 13, 2024 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Stock Crosses Above 200 Day Moving Average of $1.62

April 13, 2024 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com

April 18, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

April 2, 2024 | globenewswire.com

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

March 27, 2024 | finanznachrichten.de

MediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

March 27, 2024 | msn.com

Pre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…

March 27, 2024 | marketwatch.com

MediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment

March 27, 2024 | tmcnet.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

April 18, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

March 26, 2024 | globenewswire.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

March 20, 2024 | globenewswire.com

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

March 20, 2024 | finance.yahoo.com

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

March 12, 2024 | globenewswire.com

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

February 29, 2024 | finance.yahoo.com

MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…

February 28, 2024 | money.usnews.com

Medicinova Inc

January 17, 2024 | finanznachrichten.de

MediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

January 17, 2024 | finance.yahoo.com

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

December 21, 2023 | finance.yahoo.com

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

December 6, 2023 | markets.businessinsider.com

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

December 6, 2023 | finance.yahoo.com

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

November 27, 2023 | finance.yahoo.com

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…

November 22, 2023 | finance.yahoo.com

The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable

November 20, 2023 | msn.com

Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?

November 19, 2023 | finance.yahoo.com

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

October 28, 2023 | benzinga.com

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

October 27, 2023 | finance.yahoo.com

MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

October 12, 2023 | finance.yahoo.com

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

See More Headlines

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MNOV
CUSIP: N/A
CIK: 1226616
Web: medicinova.com
Phone: (858) 373-1500
Fax: 858-404-0048
Employees: 13
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): ($0.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,560,000.00
Net Margins: N/A
Pretax Margin: -856.80%
Return on Equity: -13.19%
Return on Assets: -12.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.61
Quick Ratio: 15.61

Sales & Book Value

Annual Sales: $1 million
Price / Sales: 70.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.27 per share
Price / Book: 1.13

Miscellaneous

Outstanding Shares: 49,050,000
Free Float: 40,757,000
Market Cap: $70.14 million
Optionable: Optionable
Beta: 0.75

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Yuichi Iwaki M.D. (Age 74)
Ph.D., Co-Founder, President, CEO & Executive Director
Comp: $933.05k
Dr. Kazuko Matsuda M.D. (Age 58)
M.P.H., Ph.D., Chief Medical Officer & Director
Comp: $653.65k
Mr. Jason J. Kruger CPA (Age 46)
CFO & Principal Financial Officer
Dr. David H. Crean M.B.A. (Age 59)
Ph.D., Chief Business Officer
Mr. John O'Neil CPA
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MNOV Stock Analysis - Frequently Asked Questions

How have MNOV shares performed in 2024?: MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV shares have decreased by 4.7% and is now trading at $1.43.
View the best growth stocks for 2024 here.
When is MediciNova's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MNOV earnings forecast.
How were MediciNova's earnings last quarter?: MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04.

What other stocks do shareholders of MediciNova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).
How do I buy shares of MediciNova?: Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNOV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial